Cure My Disease

Don't miss your cure!

 Log in / Sign up

A new tool to predict kidney failure risk in membranous nephropathy?

NCT ID NCT07785739

Knowledge-focused Sponsor: Assiut University Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting This study
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Aug 25, 2026 · Last updated Sep 03, 2026 · Updated 3 times

Summary

This study is testing whether a prediction model can accurately forecast how quickly kidney function declines in people with primary membranous nephropathy, a kidney disease that can lead to nephrotic syndrome and kidney failure. Researchers will follow 128 adults with biopsy-confirmed disease, tracking their clinical and lab results over time. The goal is to see if a simple scoring tool can help doctors identify who is at highest risk of progression, potentially guiding earlier and more aggressive treatment.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

What this could lead to
If successful, this could lead to a reliable tool for doctors to predict which patients with membranous nephropathy are at higher risk of kidney failure, enabling earlier and more personalized treatment decisions.
What could go wrong
This is an observational study, so it cannot prove cause and effect. The prediction model may not perform as well in broader populations, and the study's findings will need validation before clinical use.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

About 128 people

The number the study aims to enrol. It can still change while the study runs.

Expected to start

Aug 2026

An estimate. Start dates often move.

Expected to finish

Mar 2028

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

Adults with biopsy-proven primary membranous nephropathy attending the Nephrology Unit, Department of Internal Medicine, Assiut University Hospitals who meet the eligibility criteria.

Ages

18 years and older

Sex

Anyone

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Age ≥ 18 years * Biopsy-proven primary membranous nephropathy * Written informed consent Exclusion Criteria: * Secondary membranous nephropathy (e.g., lupus nephritis, hepatitis B or C, malignancy, drug-induced) * Pregnancy * End-stage kidney disease at presentation * Refusal to participate

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Kidney diseases are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Disease Progression idiopathic membranous glomerulonephritis kidney disorder membranous glomerulonephritis nephrotic syndrome

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Kidney diseases Membranous nephropathy Nephrotic syndrome

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  2. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

More trials for these conditions

Other studies related to the condition(s) this trial covers.